Clinical Trials Sponsored by Fujian Provincial Cancer Hospital

Total 844 results

Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy Effect | Angiogenesis
Fujian Cancer Hospital

Not yet recruiting

Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain

Hawthorn Red Combined Refractory Cancer Pain
Fujian Cancer Hospital

Not yet recruiting

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Colon Cancer
Fujian Cancer Hospital

Recruiting

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Gastric Cancer Stage IV

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy | Gastrict Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Effects of Mobile Medicine on Cancer Patients

Cancer Pain
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Fujian Cancer Hospital

Active, not recruiting

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). (ERI-Based-01)

Breast Cancer

China
Fujian Cancer Hospital

Completed

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Cancer Pain

China
Fujian Cancer Hospital

Withdrawn

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer (SIRB2)

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Unknown

Study of the Combination of Apatinib and POF

Gastric Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Non-squamous Non-small Cell Lung Cancer
Fujian Cancer Hospital

Unknown

Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer

Radiation Induced Oral Mucositis

China
Fujian Cancer Hospital

Unknown

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber)

Lung Adenocarcinoma | EGFR Mutation

China
Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
Fujian Cancer Hospital

Unknown

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

SCLC
Fujian Cancer Hospital

Unknown

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Fujian Cancer Hospital

Unknown

Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer | Total Laparoscopic Distal Gastrectomy
Fujian Cancer Hospital

Recruiting

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Leptomeningeal Metastasis

China
Fujian Cancer Hospital

Not yet recruiting

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma | Intermittent Systematic Chemotherapy
Fujian Cancer Hospital

Not yet recruiting

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Positive Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

New-mode Clinical Target Volume Delineation of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma by AJCC V8 Stage
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
Fujian Cancer Hospital

Recruiting

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Ovarian Diseases | Ovarian Neoplasms

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Fujian Cancer Hospital

Not yet recruiting

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Solid Tumors
Fujian Cancer Hospital

Not yet recruiting

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Immunotherapy
Fujian Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Fujian Cancer Hospital

Recruiting

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III
Fujian Cancer Hospital

Not yet recruiting

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Gastric Cancer
Fujian Cancer Hospital

Recruiting

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Gastric Cancer Stage III

China
Fujian Cancer Hospital

Enrolling by invitation

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

EGFR/ ALK-negative Advanced NSCLC

China
Fujian Cancer Hospital

Enrolling by invitation

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Malignant Melanomas

China
Fujian Cancer Hospital

Enrolling by invitation

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer

China
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
Fujian Cancer Hospital

Unknown

Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Completed

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Malignant Neoplasm of Stomach Stage IV

China
Fujian Cancer Hospital

Withdrawn

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Colorectal Adenocarcinoma

China
Fujian Cancer Hospital

Completed

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Cancer Pain

China

3

Subscribe